175 related articles for article (PubMed ID: 29319547)
1. The role of molecular imaging in the characterization of renal masses.
Meyer AR; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Mar; 28(2):159-165. PubMed ID: 29319547
[TBL] [Abstract][Full Text] [Related]
2. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.
Gorin MA; Rowe SP; Baras AS; Solnes LB; Ball MW; Pierorazio PM; Pavlovich CP; Epstein JI; Javadi MS; Allaf ME
Eur Urol; 2016 Mar; 69(3):413-6. PubMed ID: 26386607
[TBL] [Abstract][Full Text] [Related]
3. Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice.
Schober JP; Braun A; Ginsburg KB; Bell S; Castro Bigalli AA; Chen M; Wang R; Magee D; Bukavina L; Handorf E; Yu JQ; Chen DYT; Greenberg RE; Smaldone MC; Viterbo R; Correa AF; Uzzo RG; Kutikov A
J Urol; 2023 Sep; 210(3):438-445. PubMed ID: 37378576
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive determination of renal tumor histology utilizing molecular imaging.
Gorin MA; Rowe SP; Allaf ME
Urol Oncol; 2016 Dec; 34(12):525-528. PubMed ID: 27888980
[No Abstract] [Full Text] [Related]
5. Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses.
Sheikhbahaei S; Jones CS; Porter KK; Rowe SP; Gorin MA; Baras AS; Pierorazio PM; Ball MW; Higuchi T; Johnson PT; Solnes LB; Epstein JI; Allaf ME; Javadi MS
Clin Nucl Med; 2017 Apr; 42(4):e188-e193. PubMed ID: 28114223
[TBL] [Abstract][Full Text] [Related]
6. Use of quantitative SPECT/CT reconstruction in
Jones KM; Solnes LB; Rowe SP; Gorin MA; Sheikhbahaei S; Fung G; Frey EC; Allaf ME; Du Y; Javadi MS
Ann Nucl Med; 2018 Feb; 32(2):87-93. PubMed ID: 29214562
[TBL] [Abstract][Full Text] [Related]
7. Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.
Roussel E; Capitanio U; Kutikov A; Oosterwijk E; Pedrosa I; Rowe SP; Gorin MA
Eur Urol; 2022 May; 81(5):476-488. PubMed ID: 35216855
[TBL] [Abstract][Full Text] [Related]
8. Characterizing Indeterminate Renal Masses with Molecular Imaging: the Role of
Reynolds AM; Porter KK
Curr Urol Rep; 2017 Sep; 18(11):86. PubMed ID: 28900880
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous Regression of a Low-Grade Renal Cell Carcinoma With Oncocytic Features After Renal Mass Biopsy.
Srivastava A; Meyer AR; Pierorazio PM; Rowe SP; Allaf ME; Gorin MA
Clin Genitourin Cancer; 2018 Dec; 16(6):e1083-e1085. PubMed ID: 30097254
[No Abstract] [Full Text] [Related]
10. 99m Tc-MIBI SPECT/CT Evaluation of a Renal Collision Tumor.
Ali AA; Sivathapandi T; Gupta R; Master VA; Marcus C
Clin Nucl Med; 2023 Aug; 48(8):e390-e392. PubMed ID: 37335313
[TBL] [Abstract][Full Text] [Related]
11. The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?
Asi T; Tuncali MÇ; Tuncel M; Alkanat NEİ; Hazir B; Kösemehmetoğlu K; Baydar DE; Akdoğan B
Urol Oncol; 2020 Dec; 38(12):937.e11-937.e17. PubMed ID: 32859460
[TBL] [Abstract][Full Text] [Related]
12. The Role of
Basile G; Fallara G; Verri P; Uleri A; Chiti A; Gianolli L; Pepe G; Tedde A; Algaba F; Territo A; Sanguedolce F; Larcher A; Gallioli A; Palou J; Montorsi F; Capitanio U; Breda A
Eur Urol; 2024 Jan; 85(1):63-71. PubMed ID: 37673752
[TBL] [Abstract][Full Text] [Related]
13. Use of
Almassi N; Gorin MA; Purysko AS; Rowe SP; Kaouk J; Allaf ME; Campbell SC; Rhee A
Urology; 2018 Mar; 113():206-208. PubMed ID: 29174943
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness Analysis of
Su ZT; Patel HD; Huang MM; Meyer AR; Pavlovich CP; Pierorazio PM; Javadi MS; Allaf ME; Rowe SP; Gorin MA
Eur Urol Focus; 2021 Jul; 7(4):827-834. PubMed ID: 32115400
[TBL] [Abstract][Full Text] [Related]
15. 99m Tc-MIBI SPECT/CT in a Case of Renal Oncocytosis.
Zhao Q; Dong A; Zuo C; Yang B
Clin Nucl Med; 2023 Sep; 48(9):830-832. PubMed ID: 37486723
[TBL] [Abstract][Full Text] [Related]
16. 'Case of the Month' from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK:
Miller J; Campain N; Boydell AR; Warren H; Vito I; Neves J; Mumtaz F; Bex A; El-Shiekh S; Wagner T; Tran MGB
BJU Int; 2022 Jan; 129(1):28-31. PubMed ID: 34967994
[No Abstract] [Full Text] [Related]
17. Positron Emission Tomography/Computed Tomography with
Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Accuracy of
Parihar AS; Mhlanga J; Ronstrom C; Schmidt LR; Figenshau RS; Dehdashti F; Wahl RL
J Nucl Med; 2023 Jan; 64(1):90-95. PubMed ID: 35772963
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
[TBL] [Abstract][Full Text] [Related]
20. Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms.
Dhyani M; Grajo JR; Rodriguez D; Chen Z; Feldman A; Tambouret R; Gervais DA; Arellano RS; Hahn PF; Samir AE
Abdom Radiol (NY); 2017 Jun; 42(6):1734-1743. PubMed ID: 28197683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
